Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?

J Am Acad Dermatol. 2012 Nov;67(5):1083-5. doi: 10.1016/j.jaad.2012.05.010.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD / metabolism*
  • Antigens, Neoplasm / metabolism*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • CD52 Antigen
  • Flow Cytometry
  • Glycoproteins / metabolism*
  • Humans
  • Sezary Syndrome / drug therapy*
  • Sezary Syndrome / metabolism*
  • Skin Neoplasms / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab